El interés en corto de Cyclerion Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cyclerion Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Cyclerion Therapeutics (NASDAQ:CYCN) Bolsa, Informe de interés en corto

Cyclerion Therapeutics

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics Inc

Trading Ideas

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 256.4%

Financial giants have made a conspicuous bearish move on Applied Optoelectronics. Our analysis of options history for Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) revealed 21 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $432,603, and 15 were calls, valued at $986,947.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $50.0 for Applied Optoelectronics during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Applied Optoelectronics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Optoelectronics's whale activity within a strike price range from $22.5 to $50.0 in the last 30 days. 
<h3>Applied Optoelectronics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734969631_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$17.5</td>
<td>$16.5</td>
<td>$17.4</td>
<td>$22.50</td>
<td>$132.2K</td>
<td>1.7K</td>
<td align="right">46</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.5</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$35.00</td>
<td>$130.0K</td>
<td>2.8K</td>
<td align="right">205</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.4</td>
<td>$5.62</td>
<td>$35.00</td>
<td>$113.3K</td>
<td>2</td>
<td align="right">447</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.2</td>
<td>$6.5</td>
<td>$45.00</td>
<td>$97.5K</td>
<td>1.3K</td>
<td align="right">250</td>
</tr>
<tr>
<td>AAOI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.65</td>
<td>$35.00</td>
<td>$92.8K</td>
<td>2</td>
<td align="right">808</td>
</tr>
</tbody>
</table>

<h3>About Applied Optoelectronics</h3>
Applied Optoelectronics Inc is a provider of fiber-optic networking products for the Internet data center, cable television, telecommunications and fiber-to-the-home end markets. The company focuses on designing and manufacturing a range of optical communication products from components, to subassemblies, and modules to complete turn-key equipment. Demand for Applied Optoelectronics is driven by bandwidth demand in end markets. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The company derives maximum revenue from Taiwan.
In light of the recent options history for Applied Optoelectronics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Applied Optoelectronics Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,020,369, the price of AAOI is down by -2.23%, reaching $36.98.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 59 days from now.</li>
</ul>
<h3>Expert Opinions on Applied Optoelectronics</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $34.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Northland Capital Markets downgraded its rating to Outperform, setting a price target of $40. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Applied Optoelectronics, maintaining a target price of $44. 
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Sell, adjusting the price target to $14. 
&#x2A; An analyst from Raymond James persists with their Outperform rating on Applied Optoelectronics, maintaining a target price of $39. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Applied Optoelectronics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

AAOI

Applied Optoelectronics's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bullish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 19 unusual trades.
Delving into the details, we found 52% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $776,760, and 13 were calls, valued at $1,132,509.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $390.0 for CrowdStrike Holdings, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for CrowdStrike Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CrowdStrike Holdings's whale activity within a strike price range from $90.0 to $390.0 in the last 30 days. 
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734969626_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$5.35</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$305.00</td>
<td>$518.5K</td>
<td>4</td>
<td>1.7K</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$160.5</td>
<td>$157.55</td>
<td>$158.05</td>
<td>$250.00</td>
<td>$316.1K</td>
<td>62</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$148.45</td>
<td>$144.05</td>
<td>$146.75</td>
<td>$270.00</td>
<td>$293.5K</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$81.8</td>
<td>$79.85</td>
<td>$81.8</td>
<td>$340.00</td>
<td>$89.9K</td>
<td>491</td>
<td>11</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.36</td>
<td>$1.35</td>
<td>$1.36</td>
<td>$300.00</td>
<td>$85.1K</td>
<td>5.0K</td>
<td>635</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>CrowdStrike Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,143,560, the CRWD's price is down by -1.04%, now at $358.51. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 71 days.</li>
</ul>
<h3>Expert Opinions on CrowdStrike Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $398.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on CrowdStrike Holdings, which currently sits at a price target of $365. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on CrowdStrike Holdings with a target price of $400. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on CrowdStrike Holdings with a target price of $400. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on CrowdStrike Holdings with a target price of $450. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for CrowdStrike Holdings, targeting a price of $375. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CrowdStrike Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CRWD

Check Out What Whales Are Doing With CRWD

Financial giants have made a conspicuous bearish move on Newmont. Our analysis of options history for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) revealed 17 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,501,139, and 7 were calls, valued at $711,269.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $55.0 for Newmont over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Newmont stands at 2141.25, with a total volume reaching 3,328.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Newmont, situated within the strike price corridor from $35.0 to $55.0, throughout the last 30 days.
<h3>Newmont Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734969621_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.3</td>
<td>$17.15</td>
<td>$17.25</td>
<td>$55.00</td>
<td>$391.5K</td>
<td>118</td>
<td align="right">228</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$17.5</td>
<td>$17.4</td>
<td>$17.5</td>
<td>$55.00</td>
<td>$322.0K</td>
<td>118</td>
<td align="right">436</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$4.95</td>
<td>$6.0</td>
<td>$37.50</td>
<td>$300.6K</td>
<td>8.9K</td>
<td align="right">510</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.65</td>
<td>$8.55</td>
<td>$8.65</td>
<td>$45.00</td>
<td>$257.7K</td>
<td>4.8K</td>
<td align="right">302</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$42.50</td>
<td>$173.3K</td>
<td>3.1K</td>
<td align="right">300</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
In light of the recent options history for Newmont, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Newmont</h3>
<ul>
<li>Currently trading with a volume of 1,927,050, the NEM's price is down by -1.89%, now at $37.55. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 59 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Newmont options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Newmont

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 28.92% on an annualized basis producing an average annual return of 39.92%. Currently, Tesla has a market capitalization of $1.37 trillion. 
Buying $1000 In TSLA: If an investor had bought $1000 of TSLA stock 10 years ago, it would be worth $28,316.31 today based on a price of $425.27 for TSLA at the time of writing.
<h3>Tesla's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734969609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

TSLA

$1000 Invested In Tesla 10 Years Ago Would Be Worth This Much Today

Trident Acquisitions Corp Units (1 Ord & 1 War)

TDACU

Trading Halt: Halt status updated at 11:00:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital increased Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $550. Loop Capital analyst Eric Beder maintained a Buy rating. Microsoft shares closed at $436.60 on Friday. See how other analysts view this stock.</li>
<li>Truist Securities cut the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $550 to $460. Truist Securities analyst Joon Lee maintained a Buy rating. Vertex Pharmaceuticals shares closed at $397.27 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs lowered the price target for Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $190 to $162. Goldman Sachs analyst Susan Maklari maintained a Neutral rating. Lennar shares closed at $138.08 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark boosted the price target for Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) from $15 to $17. Benchmark analyst Bruce Jackson maintained a Buy rating. Humacyte shares closed at $4.64 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $185 to $205. Loop Capital analyst Mark Schappel maintained a Buy rating. Snowflake shares settled at $166.29 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital raised Uniti Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) price target from $5.5 to $6. RBC Capital analyst Bora Lee maintained a Sector Perform rating. Uniti shares closed at $5.70 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $160 to $200. Loop Capital analyst Yun Kim maintained a Buy rating. Datadog shares closed at $149.46 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut the price target for Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from $60 to $59. Stifel analyst Stephen Gengaro maintained a Buy rating. Schlumberger shares settled at $36.83 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $31 to $32. Barclays analyst Brandt Montour maintained an Overweight rating. Carnival shares closed at $26.80 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. increased SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) price target from $8 to $26. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. SoundHound AI shares closed at $21.75 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Price Target

Analyst Ratings

DDOG

HUMA

MSFT

SNOW

SOUN

UNIT

VRTX

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 210.9%

Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) shares are trading higher after the company disclosed a deal to acquire Lexmark International, Inc. from Ninestar Corporation, PAG Asia Capital, and Shanghai Shouda Investment Centre for<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42643529/xerox-to-acquire-lexmark" rel="noreferrer noopener"> $1.5 billion, including assumed liabilities</a>.
This acquisition will enhance Xerox's core print portfolio and expand its global print and managed print services business.
The acquisition of Lexmark will integrate its solutions with Xerox ConnectKey technology and advanced Print and Digital Services, enhancing Xerox's offering portfolio and reinforcing its commitment to adding value for clients and partners.
It will also boost Xerox's ability to serve clients in the expanding A4 color market while diversifying its distribution and geographic footprint, particularly in the APAC region.
Benefits &amp; Synergies: The combined entity will serve over 200,000 clients across 170 countries, with 125 manufacturing and distribution facilities in 16 countries.
The transaction will immediately lower Xerox's pro forma gross debt leverage ratio from 6.0x as of September 30, 2024, to around 5.4x before synergies.
After realizing $200 million in cost synergies, the ratio is expected to drop to approximately 4.4x. Xerox aims to reduce its gross debt leverage ratio to below 3.0x in the medium term.
The transaction is expected to be immediately accretive to both <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">earnings per share and free cash flow</a>.
Dividend Cut: Xerox's Board of Directors approved a reduction in the annual dividend from $1 per share to 50 cents per share, starting with the dividend expected in the first quarter of 2025.
The company said this decrease in the dividend will free up additional funds for debt reduction while offering shareholders an above-market yield.
The Xerox Board has unanimously approved the transaction, which is subject to regulatory approvals, Ninestar's shareholder approval, and other customary closing conditions.
The deal is expected to close in the second half of 2025, with both Xerox and Lexmark continuing their operations independently until then.
Xerox held $521 million in cash and equivalents <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41599453/xerox-clocks-7th-consecutive-revenue-miss-quarter-in-q3-slashes-2024-outlook-stock-tanks" rel="noreferrer noopener">as of September 30, 2024</a>.
Price Action: XRX shares are up 7.27% at $9.01 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42647780" target="_blank" rel="noreferrer noopener">Despegar To Be Acquired By Prosus For $1.7 Billion in All Cash Deal</a></li>
</ul>
Photo by Mats Wiklund via Shutterstock

Equities

Large Cap

Guidance

Movers

Xerox to Expand Global Print Business with $1.5 Billion Lexmark Buyout

Shares of General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) are little changed Monday despite news that rivals Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) and Nissan Motor Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) <a href="https://www.benzinga.com/24/12/42642773/honda-nissan-start-merger-talks">are discussing a merger</a>. 
This would create the world's third-largest automaker.
It is not clear how this would affect the long-term prospects of GM. But in the short term, the recent downtrend may be over. The stage may be set for a rally. This is why we have made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
Some analysts believe that markets are efficient and stocks follow a ‘random walk'. They are wrong. If the markets were random, all price levels would have equal importance. Clearly, that's not the case in the markets.
As you can see on the chart below, the $50.00 level has been important for GM since August. It was well-defined resistance and now it has converted into a support level.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-1024x562.png" alt="" class="wp-image-704471" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23105205/15-1.png 1489w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
From a traditional fundamental analysis point of view, there is no reason why a stock should turn when it reaches a round level like GM did. But from a technical analysis perspective, the reason why is clear. It is because of investor and trader psychology.
Read Also: <a href="https://www.benzinga.com/24/12/42553394/chargepoint-inks-pact-with-general-motors-eyes-installing-ultra-fast-charging-ports-at-key-locations">ChargePoint Inks Pact With General Motors &#8211; Eyes Installing Ultra-fast Charging Ports At Key Locations</a>
People like to place orders at nice round levels, and that is what happened here.
In addition, there is support at the $50.00 level because it had been resistance. In the financial markets support forming at levels that were previously resistance is a common occurrence. It also is because of investor and trader psychology.
It is due to ‘seller's remorse'.
When the $50.00 resistance was broken and the price moved higher, a number of the people who sold shares at the resistance decided that the decision to sell was a mistake. Some vowed to buy their shares back if they can do so at the same price they were sold at.
As a result, when the stock fell back to $50.00, they placed buy orders. The large concentration of these orders formed support.
Some of these buyers may become concerned others will be willing to pay higher prices and they know this is who the sellers will go to. So, they may increase the prices they are willing to pay. Others will see this and may do the same.
It could result in a bidding war or snowball effect that forces GM into a new uptrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a></li>
</ul>
Image: Shutterstock

Technicals

NSANY

Stock Of The Day: Is The General Motors Downtrend Over?

News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>) shares are trading higher on Monday. On Sunday, the company inked a deal to sell its Foxtel Group to DAZN Group Limited for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42639259/news-corp-announces-agreement-to-sell-foxtel-to-dazn-for-enterprise-value-of-a-3-4-billion" rel="noreferrer noopener">an enterprise value</a> of roughly $2.12 billion (AU$3.4 billion).
As part of the deal, News Corp&#8217;s shareholder loans of AU$ 578 million will be fully repaid in cash at closing.
Foxtel&#8217;s debt will be refinanced and transferred, with News Corp retaining a 6% equity stake in DAZN and a seat on its Board of Directors.
Telstra Group Ltd will also sell its minority stake in Foxtel, receive repayment of A$128 million in shareholder loans, and acquire a 3% equity interest in DAZN.7x its fiscal 2024 EBITDA.
The sale of Foxtel follows a strategic and financial review by News Corp as part of its efforts to optimize its portfolio and simplify its structure.
The deal with DAZN, known for its global reach, technology, and extensive content, will further strengthen Foxtel&#8217;s position as a digital-first, streaming-focused company, with Patrick Delany continuing as CEO.
This transaction allows News Corp to sharpen its focus on key growth areas: Dow Jones, Digital Real Estate Services, and Book Publishing.
Additionally, News Corp will maintain a stake in DAZN, a rapidly growing global sports streaming platform with over 300 million viewers across 200 markets.
The transaction is expected to close in the second half of fiscal 2025, subject to regulatory approvals and other customary conditions.
From a financial reporting perspective, Foxtel will be classified as discontinued operations starting in the second quarter of FY25.
News Corp Chief Executive Robert Thomson said, &#8220;Foxtel has been transformed into a genuine digital and streaming leader in Australia, and we believe DAZN is the right owner to take the business to the next level with their technological capabilities, global footprint and compelling sports rights.
&#8221;This transaction also allows News Corp to focus on our other growth pillars of Dow Jones, Digital Real Estate and Book Publishing, while benefiting from repayment of our shareholder loans and an improved credit profile.&#8221;
Shay Segev, DAZN&#8217;s Chief Executive Officer, added, &#8220;Australians watch more sport than any other country in the world, which makes this deal an incredibly exciting opportunity for DAZN to enter a key market, marking another step in our long-term strategy to become the global home of sport.&#8221;
As of September 30, NWS&#8217;s cash and cash <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41824310/news-corporation-reports-first-quarter-results-for-fiscal-2025" rel="noreferrer noopener">equivalents stood at $1.78 billion</a>.
Investors can gain exposure to the stock via ETF Opportunities Trust Tuttle Capital Shareholders First Index ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ESGX#BATS">ESGX</a>).
Price Action: NWS shares are up 0.36% at $30.81 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42401401/murdoch-succession-plan-faces-setback-as-commissioner-rejects-eldest-sons-control" target="_blank" rel="noreferrer noopener">Murdoch Succession Plan Faces Setback As Commissioner Rejects Eldest Son&#8217;s Control</a></li>
</ul>

ETF Opportunities Trust Tuttle Capital Shareholders First Index ETF

ESGX

News Corp Sells Foxtel to DAZN for $2.12 Billion, Retains Stake in Global Sports Streaming

Deep-pocketed investors have adopted a bullish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 16 are puts, totaling $802,286, and 4 are calls, amounting to $156,510.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $170.0 for Trade Desk during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Trade Desk options trades today is 493.67 with a total volume of 5,958.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Trade Desk's big money trades within a strike price range of $110.0 to $170.0 over the last 30 days.
<h3>Trade Desk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734968728_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$120.00</td>
<td>$155.2K</td>
<td align="right">55</td>
<td align="right">0</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$5.2</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$120.00</td>
<td>$67.5K</td>
<td align="right">99</td>
<td align="right">150</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.35</td>
<td>$4.05</td>
<td>$4.35</td>
<td>$110.00</td>
<td>$65.2K</td>
<td align="right">59</td>
<td align="right">161</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$120.00</td>
<td>$63.7K</td>
<td align="right">55</td>
<td align="right">312</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.7</td>
<td>$110.00</td>
<td>$47.0K</td>
<td align="right">59</td>
<td align="right">423</td>
</tr>
</tbody>
</table>

<h3>About Trade Desk</h3>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
In light of the recent options history for Trade Desk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 528,990, with TTD's price down by -2.3%, positioned at $122.14.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $139.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $135. 
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Outperform, setting a price target of $133. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Trade Desk, maintaining a target price of $155. 
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $135. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Trade Desk's Options Frenzy: What You Need to Know

Investors with significant funds have taken a bullish position in TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TMDX usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for TransMedics Gr. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 33% bearish. Of all the options we discovered, 8 are puts, valued at $933,494, and there was a single call, worth $25,600.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $135.0 for TransMedics Gr, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in TransMedics Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to TransMedics Gr's substantial trades, within a strike price spectrum from $60.0 to $135.0 over the preceding 30 days.
<h3>TransMedics Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734968723_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$78.0</td>
<td>$73.2</td>
<td>$75.0</td>
<td>$135.00</td>
<td>$300.0K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$73.9</td>
<td>$73.8</td>
<td>$73.8</td>
<td>$135.00</td>
<td>$244.0K</td>
<td align="right">43</td>
<td align="right">33</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$32.5</td>
<td>$28.9</td>
<td>$28.91</td>
<td>$80.00</td>
<td>$144.5K</td>
<td align="right">141</td>
<td align="right">50</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$47.8</td>
<td>$43.6</td>
<td>$45.56</td>
<td>$100.00</td>
<td>$82.0K</td>
<td align="right">37</td>
<td align="right">18</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.0</td>
<td>$18.0</td>
<td>$20.0</td>
<td>$65.00</td>
<td>$80.0K</td>
<td align="right">89</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About TransMedics Gr</h3>
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
<h3>Present Market Standing of TransMedics Gr</h3>
<ul>
<li>With a trading volume of 288,303, the price of TMDX is up by 1.87%, reaching $62.85.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for TransMedics Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TMDX

Market Whales and Their Recent Bets on TMDX Options

Investors with a lot of money to spend have taken a bullish stance on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Nike.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.
Out of all of the options we uncovered, 12 are puts, for a total amount of $626,297, and there was 1 call, for a total amount of $36,670.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $100.0 for Nike during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Nike's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Nike's substantial trades, within a strike price spectrum from $70.0 to $100.0 over the preceding 30 days.
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734968717_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$21.8</td>
<td>$100.00</td>
<td>$183.1K</td>
<td align="right">4</td>
<td align="right">84</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.34</td>
<td>$85.00</td>
<td>$55.8K</td>
<td align="right">477</td>
<td align="right">204</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$85.00</td>
<td>$55.6K</td>
<td align="right">477</td>
<td align="right">271</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.5</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$82.50</td>
<td>$55.0K</td>
<td align="right">324</td>
<td align="right">176</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.25</td>
<td>$17.65</td>
<td>$18.17</td>
<td>$95.00</td>
<td>$50.8K</td>
<td align="right">20</td>
<td align="right">29</td>
</tr>
</tbody>
</table>

<h3>About Nike</h3>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Having examined the options trading patterns of Nike, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Nike</h3>
<ul>
<li>Trading volume stands at 3,639,215, with NKE's price down by -0.08%, positioned at $76.88.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nike</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $77.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Nike with a target price of $75. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Nike, targeting a price of $73. 
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Nike, maintaining a target price of $82. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Nike, which currently sits at a price target of $73. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nike with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Nike Unusual Options Activity

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst David Stanton downgraded the rating for Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday. <a href="https://www.benzinga.com/quote/MESO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded Applied Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform. Applied Therapeutics shares closed at $0.8801 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Thomas Catherwood downgraded the rating for Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral. NCR Atleos shares closed at $73.66 on Friday. <a href="https://www.benzinga.com/quote/IIPR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MESO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png" alt="" class="wp-image-704457" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Downgrades

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

SoundHound AI Option Alert: Jan 3 $21 Calls Sweep (21) Near The Ask: 483 @ $2.401 Vs 834 OI; Ref=$20.83

Shares of autonomous driving technology leader Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a href="https://www.benzinga.com/24/11/42228142/symbotic-unusual-machines-vci-global-pony-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">debuted on Nasdaq in November</a>.
The Fremont, California-based company has the largest fleet of Level 4 autonomous mobility, offering robotaxi and robotruck services across China, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/635ac86c2048c300015a37cd/allen-chang">Analyst Allen Chang</a> initiated coverage of Pony AI with a Buy rating and a price target of $19.60.
The Pony AI Thesis: The company is the first to operate completely driverless robotaxis in four tier-1 cities in China, having obtained regulatory permits for providing robotaxi services to the general public, Chang said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
While competition is a concern, it will take time for other companies to develop a vehicle that does not need any safety drivers to offer a better riding experience to passengers versus traditional taxis, the analyst stated. 
"Besides, it also takes time to accumulate autonomous driving mileage / track record to earn the operation license from governments," he added.
"Pony AI continues to make progress on robotaxi commercialization, and we expect a revenue CAGR of 27% in 2024-27E on ramp up of its robotaxi fleet operation and start of licenses fee contribution from robotaxi solutions, then a 158% CAGR over 2027-30E with accelerated scale expansion, driving EBITDA and NI to turn positive in 2030E," Chang further wrote.
Price Action: Shares of Pony AI had risen by 4.48% to $13.75 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42230178/chinas-robotaxi-firm-looks-to-diversify-supply-chain-as-nasdaq-debut-sees-disappointment-amid-global-competition-with-tesla-waymo-and-amazon">China&#8217;s Robotaxi Firm Pony AI Looks To Diversify Supply Chain After Nasdaq Debut, Growing Competition With Tesla, Waymo, And Amazon</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Initiation

PONY

Pony AI Speeds Past Competitors, Commercializes Fully Driverless Vehicles

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on NCR Atleos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OMER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

NATL

OMER

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

RELI

Reliance Global Shares Resume Trade

Reliance Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 290.8%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the fourth quarter of 2023.<ul><li>Cyclerion Therapeutics reported earnings per share of -$1.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/cycn-stock-earnings-cyclerion-therapeutics-for-q4-of-2023/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) just reported results for the first quarter of 2024.<ul><li>Cyclerion Therapeutics reported earnings per share of -62 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cycn-stock-earnings-cyclerion-therapeutics-for-q1-of-2024/">CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks are a bankruptcy filing, regulator approval, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) stock is rocketing more than 111% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318405643&amp;type=PDF&amp;symbol=SPEC&amp;cdn=402f87b97cb330efbad1632693edb216&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">letter, settlement and asset purchase agreements</a>.</li>



<li>Trinity Place (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tphs-stock-quote/">TPHS</a>) shares are soaring over 52% with heavy pre-market trading today.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) stock is surging more than 45% <a href="https://finance.yahoo.com/news/dermtech-files-voluntary-chapter-11-120500056.html">despite a recent bankruptcy filing</a>.</li>



<li>Sarepta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) shares are gaining over 37% on <a href="https://www.marketwatch.com/story/sarepta-shares-soar-37-following-expanded-approval-for-elevidys-991d6de5?mod=home-page">expanded regulator approval</a>.</li>



<li>Kintara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/">KTRA</a>) stock is increasing 27% with strong early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares are rising more than 16% with heavy trading today.</li>



<li>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) stock is climbing close to 16% despite a lack of news today.</li>



<li>Simpple (NASDAQ:<a href="https://investorplace.com/stock-quotes/sppl-stock-quote/">SPPL</a>) shares are jumping nearly 15% without any clear news today.</li>



<li>Lion Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/lghl-stock-quote/">LGHL</a>) stock is heading over 13% higher on Friday morning.</li>



<li>Solid Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sldb-stock-quote/">SLDB</a>) shares are up more than 13% without any news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Abacus Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/abl-stock-quote/">ABL</a>) stock is diving over 23% after <a href="https://www.nasdaq.com/press-release/abacus-life-announces-pricing-public-offering-common-stock-2024-06-20">pricing a public offering</a>.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) shares are tumbling 20% on Friday morning.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is taking a more than 18% beating with strong early morning trading.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) shares are sliding over 17% on Friday morning.</li>



<li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is dropping 16% today.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are falling more than 15% <a href="https://investorplace.com/2024/06/why-is-reliance-global-reli-stock-up-283-today/">after a recent rally</a>.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock is retreating over 14% <a href="https://investorplace.com/2024/06/why-is-mgo-global-mgol-stock-up-133-today/">following a rally yesterday</a>.</li>



<li>Cyclerion Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cycn-stock-quote/">CYCN</a>) shares are decreasing 14% this morning.</li>



<li>Perfect (NYSE:<a href="https://investorplace.com/stock-quotes/perf-stock-quote/">PERF</a>) stock is slipping more than 12% today.</li>



<li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-june-21st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Cyclerion Therapeutics (CYCN). Regina Graul, Ph.D., has been promoted to Chief Executive Officer, as announced ...

Cyclerion Therapeutics Appoints New CEO Regina Graul

Cyclerion Therapeutics names Regina Graul as CEO

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Cyclerion Therapeutics (CYCN) announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its l...

Cyclerion Therapeutics announces update on next stage of growth

Cyclerion Therapeutics ( ($CYCN) ) has provided an announcement. Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Ake...

Comments

Cyclerion Therapeutics

Interés en corto

Cyclerion Therapeutics (NASDAQ:CYCN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL